NasdaqGS:DYNBiotechs
The Bull Case For Dyne Therapeutics (DYN) Could Change Following FDA Clearance Of DYNE-302 Trial
In July 2026, Dyne Therapeutics, Inc. reported a wider second-quarter net loss of US$178.56 million, or US$1.08 per share, alongside FDA clearance to begin a Phase 1 trial of DYNE-302 for facioscapulohumeral muscular dystrophy.
This marks Dyne’s third clinical program built on its FORCE platform and targets a rare muscle disease with no approved therapies, highlighting the company’s focus on genetically defined neuromuscular conditions.
With this new FDA-cleared Phase 1 trial for DYNE-302,...